688180.SH
Shanghai Junshi Biosciences Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 34.85
−6.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.0B | 2.5B | 1.9B | 1.5B | 1.5B |
| Cost of Revenue | 561.5M | 466.5M | 410.7M | 541.0M | 504.3M |
| Gross Profit | 2.5B | 2.0B | 1.5B | 961.6M | 949.2M |
| Operating Expenses | |||||
| R&D Expense | 1.3B | 1.3B | 1.3B | 1.9B | 2.4B |
| SG&A Expense | 352.1M | — | — | — | — |
| General & Admin Expense | 437.9M | 494.4M | 523.2M | 536.4M | 569.1M |
| Selling & Marketing Expense | 817.4M | 1.1B | 984.6M | 844.4M | 715.7M |
| Other Expenses | 131.7M | — | — | — | — |
| Total Operating Expenses | 3.1B | 3.0B | 2.8B | 3.3B | 3.6B |
| Cost and Expenses | 3.7B | 3.4B | 3.2B | 3.8B | 4.1B |
| Operating Income (EBIT) | (594.9M) | (999.5M) | (1.3B) | (2.5B) | (2.7B) |
| Non-Operating | |||||
| Interest Income | 19.0M | — | — | — | — |
| Interest Expense | 27.4M | — | — | — | — |
| Net Interest Income | (8.5M) | — | — | — | — |
| Other Non-Op Income/Expense | 46.3M | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (571.5M) | (1.0B) | (1.4B) | (2.5B) | (2.7B) |
| Income Tax Expense | 13.1M | (13.9M) | 22.6M | 44.0M | (93.1M) |
| Bottom Line | |||||
| Net Income | (441.0M) | (875.2M) | (1.3B) | (2.3B) | (2.4B) |
| Earnings from Cont. Ops | (584.6M) | (1.0B) | (1.4B) | (2.5B) | (2.6B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (441.0M) | (875.2M) | (1.3B) | (2.3B) | (2.4B) |
| Per Share | |||||
| Basic EPS | (CN¥0.44) | (CN¥0.87) | (CN¥1.30) | (CN¥2.32) | (CN¥2.60) |
| Diluted EPS | (CN¥0.44) | (CN¥0.87) | (CN¥1.30) | (CN¥2.32) | (CN¥2.60) |
| Revenue Per Share | CN¥2.95 | CN¥2.48 | CN¥1.98 | CN¥1.53 | CN¥1.58 |
| Shares | |||||
| Basic Shares Outstanding | 1.0B | 1.0B | 985.3M | 984.2M | 918.5M |
| Diluted Shares Outstanding | 1.0B | 1.0B | 985.3M | 984.2M | 918.5M |
| Profitability Metrics | |||||
| EBITDA | 36.3M | (715.2M) | (1.1B) | (2.2B) | (2.4B) |
| D&A | 78.1M | 284.2M | 288.1M | 289.4M | 248.6M |
| EBIT | (41.9M) | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026